Advertisement

Search Results

Advertisement



Your search for ,maY matches 17054 pages

Showing 16651 - 16700


lung cancer
issues in oncology

Low-Dose CT Screening May Result in Overdiagnosis of Lung Cancer

In a study reported in JAMA Internal Medicine, Patz et al of the NLST Overdiagnosis Manuscript Writing Team estimated the magnitude of overdiagnosis using low-dose computed tomography (CT) screening for lung cancer in the National Lung Screening Trial (NLST). They estimated that more than 18% of...

lymphoma

Anti–PD-1 Antibody Pidilizumab Plus Rituximab Shows High Activity in Relapsed Follicular Lymphoma

Antitumor immune responses may be inhibited by immune checkpoints in the tumor microenvironment including effects of PD-1 (programmed cell death 1), a co-inhibitory receptor on tumor T cells that impairs T-cell function. In a phase II study reported in The Lancet Oncology, Westin et al assessed the ...

breast cancer

Younger Women With Younger Children Less Likely to Receive Radiation Therapy After Breast-Conserving Surgery for Breast Cancer

In a study reported in the Journal of the National Cancer Institute, Pan et al assessed factors associated with noncompliance with recommended radiation therapy following breast-conserving surgery for breast cancer. A primary factor in underuse of radiation therapy was younger patients having...

prostate cancer

No Overall Survival Benefit With Addition of Sunitinib to Prednisone in Metastatic Castration-Resistant Prostate Cancer

In a phase III trial reported in the Journal of Clinical Oncology, Michaelson et al assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to prednisone in patients with progressive metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. No...

colorectal cancer
issues in oncology

Protective Effect of Aspirin for Colorectal Cancer Is Associated With rs6983267 T Allele

It has been posited that aspirin treatment may reduce risk for colorectal cancer through inhibition of WNT/cadherin-associated protein β1 (CTNNB1, or β-catenin) signaling. In a study reported in the Journal of the National Cancer Institute, Nan et al investigated the potential role of the ...

prostate cancer

Second-Line Therapies May Benefit Patients With Castration-Resistant Prostate Cancer and Poor Performance Status

Patients with castration-resistant prostate cancer and a poor performance status who were previously treated with docetaxel may benefit from currently available second-line therapies, according to the findings of a meta-analysis by Iacovelli et al published in Prostate Cancer and Prostatic...

skin cancer
issues in oncology

Novel BRAF Fusions Identified in 'Pan-Negative' Melanomas

A study by Sosman et al has identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets. In addition, these “pan-negative” melanomas were found to be sensitive to MEK inhibitors. According to the study, BRAF fusions define a new molecular...

CALGB 40603 Trial Supports Adding Carboplatin to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

The addition of carboplatin to a neoadjuvant regimen significantly increased the rate of pathologic complete response in patients with triple-negative breast cancer. The results from the CALGB/Alliance 40603 study were reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S5-01)....

breast cancer

Adjuvant Paclitaxel/Trastuzumab Tolerable, Benefits Women With Stage I HER2-Positive, Node-Negative Breast Cancer

There may be a benefit for treating small HER2-positive tumors and this can be done with little toxicity, according to a multicenter study presented at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-04). Previous studies of chemotherapy plus anti-HER2 treatment for node-negative...

breast cancer

PIK3CA Mutations Predictive of Resistance to Neoadjuvant Therapy in HER2/HR-Positive Breast Cancers

Women with HER2-positive, hormone receptor-positive breast cancer with mutations in the PI3K/AKT pathway may respond poorly to neoadjuvant therapy, German researchers reported at the 2013 San Antonio Breast Cancer Symposium (Abstract S4-06). “We found that very few women with HER2-positive...

breast cancer

Nonsignificant Reduction in Breast Cancer Risk Seen With Low-Dose Tamoxifen in Postmenopausal Hormone Replacement Therapy Users

In postmenopausal women receiving hormone replacement therapy, low-dose tamoxifen did not significantly reduce the risk of breast cancer but did increase climacteric symptoms, according to the phase III study results presented by DeCensi et al in the Annals of Oncology. However, beneficial trends...

Increased Cardiovascular Risk Despite Healthier Lifestyle Characteristics in Hematopoietic Cell Transplant Survivors

In a study reported in the Journal of Clinical Oncology, Chow et al compared cardiovascular risk and risk factors in hematopoietic cell transplantation recipients with those in a matched general population sample. Hematopoietic cell transplantation survivors were at greater risk for cardiomyopathy, ...

breast cancer

Less Is More: Postoperative Radiation May Be Avoided in Older Women With Estrogen Receptor–Rich Tumors

Among older women with hormone receptor–positive breast cancer, it is reasonable to omit whole-breast radiation therapy after breast-conserving surgery and neoadjuvant hormone therapy if the patient’s tumors have high levels of estrogen receptor expression, but radiation should remain...

issues in oncology
breast cancer

High Levels of Immune Cells in Tumors May Identify Breast Cancer Patients Most Likely to Benefit From Trastuzumab

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab (Herceptin), according to results presented today at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-05)....

Elevated Plasma Vitamin B12 Levels Associated With Cancer Risk

High plasma levels of vitamin B12 (cobalamin) have been reported in patients with cancer of different types. In a Danish study reported in the Journal of the National Cancer Institute, Arendt et al assessed cancer risk in subjects presenting with elevated cobalamin. They found that cancer risk...

lymphoma

Biologic Doublet a Potential Front-Line Treatment in Mantle Cell Lymphoma

A high proportion of mantle cell lymphoma patients may achieve an objective and durable response to treatment with an initial chemotherapy-free regimen, according to Jia Ruan, MD, PhD, of Weill Cornell Medical College, New York, who presented the results of a multicenter phase II study at the 55th...

multiple myeloma

Updated Myeloma Trial Shows Lenalidomide Maintenance Post-Transplant Improves Progression-Free But Not Overall Survival

A new analysis of the multiple myeloma IFM 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival. This is possibly attributed to the shorter survival time after first disease...

prostate cancer

Biologic Mechanism May be Linked to Racial Disparities in Prostate Cancer

In the United States, African American men are 1.6 times more likely to develop prostate cancer and more than 2.5 times as likely to die from the disease than non-Hispanic white men, according to the U.S. Department of Health & Human Services. A study by David P. Turner, PhD, Assistant...

lymphoma

Idelalisib Achieves High Response Rates in 'Double-Refractory' Indolent NHL

In patients with indolent B-cell non-Hodgkin lymphoma (NHL) refractory to both rituximab (Rituxan) and an alkylating agent, monotherapy with the selective oral PI3K-delta inhibitor idelalisib produced a high response rate, with responses persisting for 1 year in the average patient, according to...

prostate cancer
survivorship

Long-Term Symptoms Beyond 10 Years Experienced by Prostate Cancer Survivors

Years after receiving treatment, many patients who survive prostate cancer continue to experience treatment-related symptoms, according to the findings of a study by Darwish-Yassine et al published in the Journal of Cancer Survivorship. These findings highlight the need for improvements in survivor ...

leukemia

Novel Agents IPI-145 and ABT-199 Show Encouraging Results in Phase I CLL Studies

Two novel agents—the small-molecule PI3K inhibitor IPI-145 and the Bcl-2 inhibitor ABT-199—show promising activity in chronic lymphocytic leukemia (CLL), according to two phase I studies presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstracts...

leukemia

Graft Manipulation Improves HLA-Haploidentical Hematopoietic Stem Cell Transplant Outcomes

T-cell–depleted HLA-haploidentical hematopoietic stem cell transplantation can be made more efficacious and safer through the removal of alpha/beta-positive T cells and CD19-positive B cells from the graft, an approach pioneered by Italian investigators who reported results at the 55th...

Vorinostat Plus Standard Immunoprophylaxis Cuts Risk of Graft-vs-Host Disease in Half

A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of bone marrow transplant treatments, according to a study by Choi et al published in The Lancet Oncology. The study, the first to test this treatment in humans, combined the drug vorinostat...

gynecologic cancers

Grade 3 Endometrioid Carcinoma With PIK3CA Mutation Linked to Unfavorable Outcome

The presence of PIK3CA missense mutation appears to be associated with shorter disease-specific survival in grade 3 endometrioid but not serous endometrial carcinoma, according to a study in Gynecologic Oncology. Although McIntyre et al found this type of mutation across all histologic types of...

lung cancer

Reduced Renal Function Observed in Patients Taking Crizotinib for Non‒Small Cell Lung Cancer

Patients receiving crizotinib (Xalkori) for the treatment of anaplastic lymphoma kinase (ALK)-positive non?small cell lung cancer (NSCLC) had reductions in their estimated glomerular filtration rate, according to the findings of a study by Brosnan et al published in the journal Cancer. In the...

breast cancer

Hypercholesterolemia May Drive the Growth of Breast Cancer

High levels of the cholesterol metabolite 27-hydroxycholesterol seem to function like estrogen and may independently drive the growth of breast cancer, according to the findings of a preclinical study by Nelson et al published in Science. They also found a possible connection between...

prostate cancer
issues in oncology

Genetic Mutation May Play a Role in Worse Outcomes for Obese Prostate Cancer Patients

A study by researchers from Harvard School of Public Health, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital has found that overweight or obese men with prostate cancer whose tumors were positive for the TMPRSS2:ERG genetic mutation had more than a 50% increased risk of dying...

breast cancer

Digital Breast Tomosynthesis Increases Cancer Detection and Reduces Recall Rates

Compared to traditional mammography, three-dimensional (3D) mammography—known as digital breast tomosynthesis—found 22% more breast cancers and led to fewer call-backs in a large screening study at the Hospital of the University of Pennsylvania, researchers reported today at the 99th...

head and neck cancer

Postradiotherapy Neck Dissection Improves Local Control in Head and Neck Squamous Cell Carcinoma Patients With Advanced Nodal Disease

Available data indicate that lymph node involvement predicts failure at primary and distant sites after chemoradiation for head and neck cancer. In a study reported in JAMA Otolaryngology Head & Neck Surgery, Ranck et al assessed the impact of postradiotherapy neck dissection on local and...

multiple myeloma

Three-Drug Regimen Produces High Response Rate in Relapsed/Refractory Multiple Myeloma

A phase II trial to evaluate the combination of bendamustine (Treanda) with bortezomib (Velcade) and dexamethasone in patients with relapsed/refractory multiple myeloma “showed a remarkable response rate of 60.9%, and, when minor responses were included in 75.9% of patients,”...

head and neck cancer
issues in oncology

U.S. Preventive Services Task Force Issues Final Recommendations on Screening for Oral Cancer

The U.S. Preventive Services Task Force (USPSTF) today released its final recommendation statement on screening for oral cancer in adults without signs or symptoms of oral cancer who are seen by primary care providers. This recommendation focuses on primary care professionals and is not a...

prostate cancer

Low-Fat Diet and Fish Oil Supplementation Reduces Cell-Cycle Progression in Prostate Cancer

In a post hoc analysis reported in the journal Cancer Prevention Research, Galet et al analyzed the effects of diet on men with prostate cancer. They found that men who were on a low-fat diet and fish oil supplementation had lower cell-cycle progression scores, which are associated with less...

colorectal cancer

Reduced Specialist Consultation and Multimodality Therapy May Account for Poorer Survival in Black Patients With Metastatic Colorectal Cancer

Black patients with metastatic colorectal cancer have been found to have poorer survival than white patients. In a study reported in Journal of the National Cancer Institute, Simpson et al found that black patients were less likely to have specialist consultations and to receive multimodality...

head and neck cancer

Certain Symptom Clusters After Surgery for Esophageal Cancer Predict Poor Prognosis

A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease. The findings by Wikman et al were published...

gynecologic cancers

Estrogen Levels Affect the Efficacy of PARP Inhibitors in PTEN-Deficient Endometrial Tumors

PARP inhibition appears to be an effective way to shrink PTEN-deficient endometrial tumors with low levels of estrogen but is ineffective in those with high levels of estrogen, according to preclinical study results reported by Janzen et al in Molecular Cancer Therapeutics. The findings suggest...

issues in oncology
gynecologic cancers

Epigenetic Modification of HAND2 May Be Associated With the Development of Endometrial Cancer

In a study reported in the journal PLoS One, Allison Jones, MD, of the Elizabeth Garrett Anderson Institute for Women’s Health, University College London, and colleagues analyzed the functional role of epigenetic factors in endometrial cancer development. They found that HAND2 methylation...

hematologic malignancies

Study Finds Possible Link Between Allergies and Increased Risk of Hematologic Cancers in Women

A team of researchers looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies—in particular to plants, grass, and trees—with risk of blood cancers in women. The same association was not found in men, suggesting a possible...

colorectal cancer

12-Gene Recurrence Score Independently Predicts Recurrence in Patients With Stage II/III Colon Cancer

In a study reported in Journal of Clinical Oncology, Greg Yothers, PhD, of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Biostatistical Center and the University of Pittsburgh Graduate School of Public Health, and colleagues assessed performance of the 12-gene colon cancer...

supportive care
survivorship

Internet-Based Intervention Improves Cancer-Related Sexual Dysfunction in Women

An Internet-based intervention may significantly improve both sexual function and satisfaction in women with sexual dysfunction years after treatment for breast or gynecologic cancer, according to a randomized trial reported in the November issue of the Journal of the National Comprehensive Cancer...

skin cancer

Studies Reveal Multiple Gene Alterations Responsible for Drug Resistance in BRAF-Mutated Melanoma

Two studies using whole-exome sequencing of treatment-resistant BRAF-mutated melanomas have identified multiple gene alterations, mostly affecting the MAPK pathway. Molecularly profiling BRAF-mutated melanoma patients at the time of resistance may improve their care by tailoring combinations of...

prostate cancer

Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...

hematologic malignancies
leukemia

Gemtuzumab Ozogamicin Reduces Minimal Residual Disease in Children With High-Risk Acute Myeloid Leukemia

Combining gemtuzumab ozogamicin (Mylotarg) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital. The results appear in the...

colorectal cancer

MicroRNA Signature Predicts Risk of Recurrence After Surgery for Stage II Colon Cancer

In a study reported in The Lancet Oncology, Jia-Xing Zhang, MD, of Sun Yat-sen University, and colleagues identified a six-microRNA (miRNA) signature that predicted risk of recurrence after surgery for stage II colon cancer and that may help to identify patients most likely to benefit from adjuvant ...

skin cancer
issues in oncology

New Studies Provide Insight Into Melanoma Drug Resistance Pathways and Strategy for Obtaining Durable Responses

Approximately 50% of metastatic melanomas harbor the BRAF mutation, and although most of these melanomas respond dramatically to treatment with BRAF inhibitors, such as vemurafenib (Zelboraf) and dabrafenib (Tafinlar), nearly all develop resistance to the drugs within 7 to 8 months. While previous...

lymphoma
issues in oncology

STAT3 Activation Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

In a study reported in the Journal of Clinical Oncology, Xin Huang, PhD, of the National Clinical Research Center of Cancer in Tianjin, and colleagues investigated whether STAT3 activation can identify patients with diffuse large B-cell lymphoma treated with R-CHOP (rituximab [Rituxan] plus...

colorectal cancer

Alternate VEGF Ligands Associated With Bevacizumab Resistance in Metastatic Colorectal Cancer

Results from a University of Colorado Cancer Center study indicated that bevacizumab (Avastin) resistance in patients with colorectal cancer may be due to increases in growth factors other than the targeted VEGF-A. The study, led by Christopher Lieu, MD, and published in the journal PLoS One,...

supportive care

Most Patients Experience Nocturnal Care Disturbances Following Hematopoietic Stem Cell Transplantation

In a study reported in the Clinical Journal of Oncology Nursing, Eileen Danaher Hacker, PhD, APN, AOCN, of the University of Illinois College of Nursing, and colleagues attempted to identify and quantify nocturnal care disruptions in patients undergoing hematopoietic stem cell transplantation. They ...

breast cancer

Timing and Choice of Treatment May Affect the Quality of Life of Young Breast Cancer Survivors

The choice and timing of therapeutic interventions may significantly affect the quality of life of young breast cancer survivors in the short term, although other quality-of-life domains such as family relationships may not be negatively impacted after treatment. These findings were reported by...

Study Explains Cyclophosphamide’s Role in Preventing Graft-vs-Host Disease

Results of a Johns Hopkins study may explain why cyclophosphamide prevents graft-vs-host disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of graft-vs-host...

gynecologic cancers

Assay-Sensitive Treatment Improves Outcomes in Recurrent Ovarian Cancer

The use of assay-sensitive treatment significantly improved both progression-free survival and overall survival compared with nonsensitive treatment in women with recurrent ovarian cancer, according to the results of a prospective clinical trial reported in Gynecologic Oncology. Thomas Rutherford,...

Advertisement

Advertisement




Advertisement